AYTU BIOPHARMA, INC
For the period ended Sep 23, 2025. Filed Sep 23, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 23, 2025 · Filed Sep 23, 2025
Use the contents to explore the available documents and sections.
AYTU$1.83+1.1%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except share data)
(in thousands, except share data)
| June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $30,952 | $20,006 |
| Accounts receivable, net | 31,155 | 23,526 |
| Inventories | 11,434 | 12,141 |
| Prepaid expenses and other current assets | 5,638 | 5,097 |
| Current assets of discontinued operations | — | 1,121 |
| Total current assets | 79,179 | 61,891 |
| Non-current assets: | ||
| Property and equipment, net | 532 | 693 |
| Operating lease right-of-use assets | 1,061 | 829 |
| Intangible assets, net | 42,201 | 52,453 |
| Other non-current assets | 1,204 | 2,185 |
| Non-current assets of discontinued operations | — | 44 |
| Total non-current assets | 44,998 | 56,204 |
| Total assets | $124,177 | $118,095 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $10,601 | $10,314 |
| Accrued liabilities | 38,164 | 38,143 |
| Revolving credit facility | 9,063 | 2,395 |
| Current portion of debt | 1,857 | 1,857 |
| Other current liabilities | 3,379 | 8,962 |
| Current liabilities of discontinued operations | — | 557 |
| Total current liabilities | 63,064 | 62,228 |
| Non-current liabilities: | ||
| Debt, net of current portion | 10,895 | 10,877 |
| Derivative warrant liabilities | 26,334 | 12,745 |
| Other non-current liabilities | 4,918 | 4,529 |
| Total non-current liabilities | 42,147 | 28,151 |
| Stockholders’ equity: | ||
| Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, par value $.0001; 200,000,000 shares authorized; 8,976,913 and 5,972,638 shares issued and outstanding, respectively | 1 | 1 |
| Additional paid-in capital | 352,500 | 347,688 |
| Accumulated deficit | (333,535) | (319,973) |
| Total stockholders’ equity | 18,966 | 27,716 |
| Total liabilities and stockholders’ equity | $124,177 | $118,095 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.